Pilot Study to Evaluate the Effects of a Vaccine (HSPPC-96) Combined With Ipilimumab in Patients With Advanced Melanoma

NCT02452281 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped PI departure, operational issues

Conditions

Melanoma

Interventions

DRUG: ipilimumab
DRUG: HSPPC-96

Sponsor

Rabih Said

Collaborators

[object Object]